← FDA DRUG APPROVALS

FDA ANDA · ANDA077045

CITALOPRAM

Sponsor: EPIC PHARMA

APPLICATION
ANDA077045
TYPE
ANDA
ORIGINAL APPROVAL
2005-04-29
LATEST ACTION
2024-11-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CITALOPRAM HYDROBROMIDEPrescription
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEPrescription
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEPrescription
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL

Approval history

2024-11-14Labeling · Supplement 14 · standardAP
2024-11-14Labeling · Supplement 17 · standardAP
2024-11-14Labeling · Supplement 15 · standardAP
2024-11-14Labeling · Supplement 8 · standardAP
2014-11-24Labeling · Supplement 3 · standardAP
2014-11-24Labeling · Supplement 6 · standardAP
2014-11-24Labeling · Supplement 4 · standardAP
2005-04-29Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →